市場調查報告書
商品編碼
1416182
基因分型市場-按產品和服務(試劑和試劑盒、儀器、軟體、服務)、技術(PCR、定序、微陣列)、應用(診斷和個人化醫療等)、最終用途、全球預測,2023- 2032 年Genotyping Market-By Products & Services (Reagent & Kit, Instrument, Software, Service), Technology (PCR, Sequencing, Microarray), Application (Diagnostics & Personalized Medicine, & Others), End-use, Global Forecast, 2023-2032 |
由於該領域研發活動的加強,2024 年至 2032 年間,全球基因分型市場的CAGR將達到 15.9%。隨著基因研究日益融入從醫學到農業的各個學科,對先進基因分型技術的需求激增。
例如,2023 年 6 月,Jumpcode Genomics 官員揭露了一項研究結果,展示了使用基於 CRISPR-Cas9 的體外重複去除改進的基因分型。這種創新方法涉及在基因分型之前透過低通定序去除重複片段,Genome Research 發表的題為「基於CRISPR-Cas9 的重複缺失用於複雜植物性因組高通量基因分型」的研究中證明了這一點。 Jumpcode Genetics 執行長 Yaron Hakak 博士強調了該技術在消除基因組定序庫中重複元素方面的有效性。正如研究結果所詳述,這種方法提高了編碼和調控區域基因分型的精確度。
研究人員和生物技術人員尋求更精確、更有效的基因分型方法來揭示遺傳複雜性。隨著公司努力提供創新的基因分型解決方案,促進個人化醫療、疾病理解和作物改良的突破,這種需求推動了市場。研究和開發的不斷成長勢頭凸顯了基因分型在推進科學前沿的關鍵作用。
整體基因分型市場佔有率根據產品和服務、應用和地區進行分類。
從2024年到2032年,儀器細分市場將經歷重大發展。隨著基因分型技術的不斷發展,市場對能夠實現精確和高通量基因分型的複雜儀器的需求激增。這些儀器,從 PCR 儀到 DNA 定序儀,為研究人員提供了解開遺傳複雜性的有效工具。從醫療保健到農業等各個領域擴大採用基因分型,凸顯了先進儀器在滿足準確、快速基因分型解決方案的需求方面的關鍵作用,從而塑造了基因分型市場的動態。
2024 年至 2032 年,藥物基因組學領域的基因分型市場規模將實現顯著的CAGR。藥物基因組學領域不斷擴大。隨著個人化醫療日益受到重視,精確基因分型的需求對於了解影響藥物反應的個體遺傳變異變得至關重要。基因分型在根據患者的基因譜量身訂做治療和最佳化治療結果方面發揮關鍵作用。由於藥物基因組學在醫療保健領域的重要性日益增強,對先進基因分型技術的需求持續成長,強調了市場在提供更有效和個性化的醫療干預工具方面的關鍵作用。
亞太地區基因分型產業從 2024 年到 2032 年將呈現出值得稱讚的CAGR。隨著亞太國家科學研究和醫療保健進步的激增,對複雜基因分型技術的需求日益成長。該地區不斷擴大的生物技術和製藥行業,以及不斷增加的基因研究舉措,導致對基因分型解決方案的需求增加。
亞太地區在基因組學研究和個人化醫療方面的關鍵作用凸顯了該市場在提供創新基因分型工具以滿足該地區研究人員、臨床醫生和醫療保健從業人員不斷變化的需求方面的重要性。例如,2023年11月,GC Genome和MP Group就基因分型服務SNP Genome Health在泰國的商業化簽訂了合作獨家授權協議。根據合約條款,MP Group 將獲得 GC Genome 的獨家許可,在指定地區推廣 Genome Health。作為合作的一部分,GC Genome 將提供在泰國建立基因實驗室所需的基本濕實驗室技術和專業知識。
Global Genotyping Market will witness 15.9% CAGR between 2024 and 2032, owing to heightened research and development activities in the field. As genetic studies become increasingly integral to various disciplines, from medicine to agriculture, the need for advanced genotyping technologies surges.
For instance, in June 2023, Jumpcode Genomics officials disclosed findings from a study showcasing improved genotyping using CRISPR-Cas9-based in vitro repeat depletion. This innovative approach involves removing repetitive fragments before genotyping with low-pass sequencing, demonstrated in the study titled "CRISPR-Cas9-based repeat depletion for high-throughput genotyping of complex plant genomes," Genome Research published piece. Yaron Hakak, Ph.D., CEO of Jumpcode Genetics, highlights the technology's effectiveness in eliminating repetitive elements from genome sequencing libraries. This method enhances the precision of genotyping in coding and regulatory regions, as detailed in the study's findings.
Researchers and biotechnologists seek more precise and efficient genotyping methods to unravel genetic complexities. This demand propels the market as companies strive to provide innovative genotyping solutions, facilitating breakthroughs in personalized medicine, disease understanding, and crop improvement. The rising momentum in research and development underscores the critical role of genotyping in advancing scientific frontiers.
The overall Genotyping Market share is classified based on the products and services, application, and region.
Instruments segment will undergo significant development from 2024 to 2032. As genotyping technologies continue to evolve, the market witnesses a surge in demand for sophisticated instruments that enable precise and high-throughput genotyping. These instruments, ranging from PCR machines to DNA sequencers, empower researchers with efficient tools for unraveling genetic complexities. The increasing adoption of genotyping in diverse fields, from healthcare to agriculture, underscores the pivotal role of advanced instruments in meeting the demand for accurate and rapid genotyping solutions, shaping the dynamics of the Genotyping Market.
Genotyping market size from the pharmacogenomics segment will register a noteworthy CAGR from 2024 to 2032. Expanding field of pharmacogenomics. As personalized medicine gains prominence, the need for precise genotyping becomes pivotal in understanding individual genetic variations affecting drug responses. Genotyping plays a critical role in tailoring treatments based on patient's genetic profiles and optimizing therapeutic outcomes. The demand for advanced genotyping technologies continues to rise, driven by the growing significance of pharmacogenomics in healthcare, emphasizing the market's crucial role in providing tools that enable more effective and personalized medical interventions.
Asia Pacific genotyping industry will showcase a commendable CAGR from 2024 to 2032. As scientific research and healthcare advancements surge across Asia-Pacific countries, there is a growing need for sophisticated genotyping technologies. The region's expanding biotechnology and pharmaceutical sectors, in line with increasing genetic research initiatives, contribute to the heightened demand for genotyping solutions.
The Asia-Pacific's pivotal role in genomics research and personalized medicine underscores the market's significance in providing innovative genotyping tools to meet the evolving needs of researchers, clinicians, and healthcare practitioners in the region. For instance, in November 2023, GC Genome and MP Group entered into a collaborative and exclusive license agreement for the commercialization of the genotyping service SNP Genome Health in Thailand. Under the terms of the contract, MP Group will be granted an exclusive license from GC Genome to promote Genome Health in the designated territory. GC Genome will provide the essential wet lab technology and expertise required for establishing a genetic laboratory in Thailand as part of this partnership.